Investment Rating - The industry investment rating is "Overweight" (maintained) [6] Core Insights - The construction of tightly-knit urban medical groups is a significant continuation of the reform of the medical and health system in China, aimed at improving resource allocation and healthcare service levels [8] - The National Health Commission is promoting the construction of tightly-knit urban medical groups in 81 pilot cities, which will enhance the sharing of medical resources [6][8] - By 2024, the number of two-way referrals is expected to reach 36.57 million, a 20.6% increase from 2023, indicating improved access to healthcare services [8] Summary by Sections Industry Performance - Over the past 12 months, the industry has shown relative returns of 2.53%, absolute returns of 11.5%, with a 1-month relative return of 7.65% and a 3-month return of 7.88% compared to the CSI 300 index [3] Investment Highlights - The establishment of national medical centers and regional medical centers is part of a three-tier service system that includes tightly-knit urban medical groups and county-level medical communities [8] - The government has allocated 10 billion yuan in 2024 to support the construction of tightly-knit county-level medical communities, focusing on upgrading medical equipment and hospital facilities [8] - The policy aims for 90% coverage of this system by 2025 and full coverage by 2027, which is expected to drive demand for medical equipment and services [8] Investment Recommendations - The construction of tightly-knit urban medical groups will reshape the medical industry chain, benefiting sectors such as medical devices, medical services, healthcare information technology, pharmaceutical distribution, innovative drugs, and traditional Chinese medicine [8] - Companies with technological advantages and strong grassroots channels, such as domestic medical device manufacturers and healthcare service providers, are recommended for investment [8]

Group 1 - The core viewpoint highlights a strong performance in the Chinese innovative pharmaceutical sector, with the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index rising by 2.72% as of June 12, 2025, driven by significant gains in constituent stocks such as Rongchang Bio (+17.55%) and BeiGene (+8.00%) [1] - A total of 53 new drugs were approved in China from the beginning of 2025 to the end of May, including 30 domestic innovative drugs and 23 imported ones, covering various therapeutic areas such as oncology and rare diseases [1] - The Chinese innovative drug market is projected to reach nearly 550 billion RMB in 2024, with an expected explosive growth driven by business development (BD) revenues from 2025 to 2027, and is anticipated to exceed 2 trillion RMB by 2030 [1] Group 2 - The Sci-Tech Innovation Board Biopharmaceutical Index consists of 50 large-cap companies from various sectors, including biopharmaceuticals and biomedical engineering, reflecting the overall performance of representative companies in the industry [2] - As of May 30, 2025, the top ten weighted stocks in the index accounted for 51.6% of the total index weight, with companies like United Imaging Healthcare and BeiGene among the leading constituents [2]

Group 1 - Shanghai LEGO Park, built with over 85 million LEGO bricks, is set to welcome its first visitors in July, but the company faced initial concerns regarding complex cross-border tax issues related to equipment imports and frequent external payments [1] - The tax authority in Jinshan District provided a customized "full-process" cross-border tax solution, identifying 47 tax risk points and assisting the company in completing 15 external payment filings, resulting in a tax deduction of over 6.5 million yuan [1] - The company successfully applied for a tax refund of over 85 million yuan in input tax credits and received a reduction of nearly 250,000 yuan in urban land use tax [1] Group 2 - Prior to the official project handover, the tax department formed a volunteer service team to provide targeted support for the company's 219 employees regarding their income tax filing issues, offering policy consultation and system operation guidance [2] - The tax department's risk prevention efforts are not merely about identifying problems but also about helping companies establish systems to mitigate risks, as seen in the case of GeSi Aerospace, which benefited from tax deductions totaling 4.026 million yuan for R&D expenses [4] - The Shanghai Tunnel Engineering Company received nearly 190 million yuan in R&D expense deductions, crucial for the development of key equipment like the "Qiyue" shield machine, while the tax department assisted in managing cross-regional tax issues [5] Group 3 - The tax authority in Jiading District streamlined tax policies and provided risk management guidance for the construction of the 4.5 billion yuan medical equipment production and R&D base, helping the company avoid potential tax risks [6] - Shanghai's major engineering projects for the year include 186 formal projects and 35 preparatory projects, with a total investment plan of 240 billion yuan, highlighting the proactive approach of the tax department in fostering a law-based business environment [6] - The tax department aims to create a predictable and transparent tax environment for businesses in Shanghai, ensuring that policy benefits are fully and accurately released [6]

Core Viewpoint - The healthcare sector, particularly the innovative drug and medical device industries, is experiencing significant growth driven by government policies and technological advancements, especially in AI [2][3]. Group 1: Market Performance - As of June 12, 2025, the healthcare ETF Taikang (159760) rose by 0.83%, tracking the National Public Health and Healthcare Index (980016), which increased by 0.62 [1] - Over the past two weeks leading up to June 11, 2025, the healthcare ETF Taikang (159760) accumulated a rise of 3.95% [2]. Group 2: Government Policies and Industry Outlook - In 2025, the government has continuously injected vitality into the innovative drug industry through various policies, including a comprehensive reform plan for drug and medical device regulation [2]. - Key reforms include 24 measures proposed by the State Council in January and a digital transformation plan for the pharmaceutical industry released in April [2]. Group 3: Investment Opportunities - Companies with core independent technologies and overseas authorizations are highlighted as having high growth certainty and valuation elasticity [2]. - The innovative drug sector has seen rapid growth in product revenue and external authorizations over the past three years, with significant business development (BD) transactions occurring this year [2]. - The healthcare ETF Taikang (159760) is expected to benefit from the rapid development of AI technology in the medical industry [2]. Group 4: Index Composition - The National Public Health and Healthcare Index (980016) includes companies focused on prevention, testing, and treatment, which are areas with significant potential for AI application [3]. - As of May 30, 2025, the top ten weighted stocks in the index accounted for 52.46% of the total, including companies like Heng Rui Medicine (600276) and WuXi AppTec (603259) [3].

Core Viewpoint - The performance of the Sci-Tech Innovation Pharmaceutical Index ETF has shown significant growth in both trading volume and scale, indicating strong investor interest and confidence in the sector [3][5][6]. Liquidity - The Sci-Tech Innovation Pharmaceutical Index ETF had an intraday turnover of 9.12%, with a transaction volume of 20.17 million yuan. Over the past week, the average daily transaction volume reached 50.98 million yuan, ranking first among comparable funds [3]. Scale - In the past year, the Sci-Tech Innovation Pharmaceutical Index ETF's scale increased by 143 million yuan, achieving notable growth and ranking first among comparable funds [3]. Shares - The ETF's shares grew by 120 million in the past year, also ranking first among comparable funds [3]. Top Holdings - As of May 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 51.6% of the total weight. The leading stocks include: - United Imaging Healthcare (8.97%) - BeiGene (7.05%) - Huaitai Medical (5.85%) - Aierx (4.91%) - Baillie Tianheng (4.77%) - Zai Lab (4.75%) - BGI Genomics (4.17%) - Junshi Biosciences (4.15%) - Aibo Medical (3.33%) - Teva Biopharma (3.25%) [5]. Market Response - Following the American Society of Clinical Oncology (ASCO) annual meeting, there has been a positive market response, highlighting the competitiveness and innovation of Chinese pharmaceutical companies in new drug development [5][6]. Innovation Pipeline - The proportion of domestic companies' innovative drug data presented at ASCO has been increasing, with 73 studies selected for oral presentations in 2025, indicating a strong focus on innovation within the industry [6]. Investment Opportunities - Investors without stock accounts can access opportunities in the Sci-Tech Innovation Board biopharmaceutical sector through the Sci-Tech Biopharmaceutical ETF linked fund (021061) [6].

（原标题：今日看点｜国新办将举行《关于深入推进深圳综合改革试点深化改革创新扩大开放的意见》 有关情况新闻发布会） 经济观察网讯 6月12日重点关注的财经要闻与资本市场大事： 1、国新办将举行《关于深入推进深圳综合改革试点深化改革创新扩大开放的意见》有关情况新闻发布 会 6月12日，国新办将举行两场新闻发布会。上午10时，国家发展改革委副主任李春临，广东省委常委、 常务副省长张虎，深圳市委副书记、市长覃伟中和科技部有关负责人介绍《关于深入推进深圳综合改革 试点深化改革创新扩大开放的意见》有关情况，并答记者问。 下午3时，应急管理系统代表围绕"勇担应急使命 守护人民平安"与中外记者见面交流。 2、商务部将举行新闻发布会，介绍近期商务领域重点工作有关情况 6月12日下午3时，商务部将举行新闻发布会，新闻发言人介绍近期商务领域重点工作有关情况，并答记 者问。 3、第四届中国—非洲经贸博览会将举行 6月12日至15日，第四届中国—非洲经贸博览会将在湖南长沙举行。本届博览会，非洲国家举办活动将 创历届之最。肯尼亚、津巴布韦、卢旺达、安哥拉、纳米比亚、刚果（金）等6个非洲国家将举办商务 交流活动。会期内，拟签约项目199个 ...

导读： 本文深度聚焦国内50家上市仪器公司，通过解析2024年度研发投入金额、占比、人员规模等关键数据，绘制出一份全景式创新图谱。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 科学仪器，被誉为现代工业的"隐形基石"和科技创新的"眼睛与双手"。从基础研究到产业升级，从实验室探索到高端制造，仪器的精度与可靠 性直接决定着科研的高度与产业的质量。然而，这一关键领域曾长期被国际巨头垄断，国产仪器的"卡脖子"之痛，不仅关乎企业生存，更牵系 国家科技自主的战略安全。 近年来，政策东风频吹——从"十四五"规划的顶层设计，到财政专项的精准滴灌；从进口替代的硬性指标，到产学研协同的技术攻坚，国产科 学仪器行业正迎来前所未有的历史性机遇。在这场必须打赢的"逆袭战"中，研发投入成为企业竞争力的核心标尺：唯有真金白银砸向创新，才 能突破技术壁垒；唯有顶尖人才汇聚，方能锻造出与进口品牌抗衡的"中国精度"。 基于此，仪器信息网深度聚焦国内50家上市仪器企业，通过解析2024年度研发投入金额、占比、人员规模等关键数据，绘制出一份全景式创 新图谱。我们试图回答：谁在引 ...

Group 1: Liquidity and Performance of Sci-Tech Pharmaceutical Index ETF - The Sci-Tech Pharmaceutical Index ETF had a turnover rate of 16.48% during the trading session, with a transaction volume of 37.98 million yuan, indicating active market trading [2] - Over the past week, the average daily transaction volume of the ETF reached 48.92 million yuan, ranking first among comparable funds [2] - In the past year, the ETF's scale increased by 154 million yuan, achieving significant growth and ranking first in new scale among comparable funds [2] - The ETF's shares grew by 130 million units in the past year, also ranking first in new shares among comparable funds [2] - As of June 10, the net value of the ETF increased by 25.51% over the past year [2] - The highest monthly return since inception was 23.29%, with the longest consecutive monthly gains being 4 months and a maximum increase of 21.76% [2] - The average monthly return during the rising months was 8.18%, with a historical one-year profit probability of 69.81% [2] Group 2: Market Trends and Investment Opportunities - The Central Committee of the Communist Party of China and the State Council issued opinions to improve the basic medical insurance drug catalog adjustment mechanism and to develop a commercial health insurance innovative drug catalog [3] - A report from Dongwu Securities indicated that there were 73 oral presentations from China at the 2025 ASCO, marking a historical high, with 89 out of 184 ADC pipeline studies coming from China, accounting for approximately 48.4% of the total [3] - The agency believes that the competitiveness of domestic innovative drugs in the global market is continuously improving, and international investors' confidence in Chinese innovative drug companies is increasing [3] - Domestic innovative drugs are transitioning from "catching up" to "leading," presenting significant investment opportunities [3] - Investors without stock accounts can access the Sci-Tech Biopharmaceutical ETF linked fund (021061) to capitalize on opportunities in the Sci-Tech Board biopharmaceutical sector [3]

Group 1: Strategic Emerging Industries Development - The government work report emphasizes the promotion of integrated cluster development in strategic emerging industries, highlighting the formation of substantial industrial clusters in the Sci-Tech Innovation Board [1] - The Sci-Tech Innovation Board has 113 listed companies in the biopharmaceutical sector, focusing on treatments for cancer, AIDS, and hepatitis B, making it a major listing venue globally outside the US and Hong Kong [1] - In the integrated circuit sector, there are 119 companies, representing a significant portion of A-share listed companies, with a complete industrial chain from chip design to packaging and testing [1] Group 2: Biopharmaceutical Sector Innovations - The National Medical Products Administration approved 11 new drugs, with five from Sci-Tech Innovation Board companies, indicating a strong performance in drug innovation [2] - Eight new drugs have been approved for Sci-Tech Innovation Board innovative drug companies this year, with a total of 33 globally new class 1 drugs launched since 2018, accounting for 14% of domestic approvals [2] - The medical device sector has seen increased domestic production rates for high-end imaging equipment, with companies establishing resilient supply chains [2] Group 3: Integrated Circuit Industry Growth - The integrated circuit sector reported a net profit of 4.479 billion yuan in Q1, a 73% year-on-year increase, driven by domestic substitution and demand recovery [4] - Companies in the chip design and semiconductor equipment sectors have shown significant revenue and profit growth, with some companies like Hengxuan Technology achieving a 590.22% increase in net profit [4][5] - The production capacity and order status of wafer manufacturing companies remain strong, with major players like SMIC and Huahong maintaining high utilization rates [5] Group 4: Strategic Expansion and Internationalization - Companies in the Sci-Tech Innovation Board are exploring mergers and acquisitions to achieve external growth, with recent announcements of mergers such as Haiguang Information and Zhongke Shuguang [6] - The internationalization of biopharmaceutical companies is accelerating, with 11 companies granting overseas rights to their innovative drugs, marking a significant step towards global market entry [7] - The collaboration between domestic companies and global research institutions is increasing, with over 55 top research institutions engaged in partnerships, facilitating the global transformation of innovative results [7]

Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index, which reflects the overall performance of up to 30 listed companies in the medical sector on the Sci-Tech Innovation Board [1] - The Shanghai Sci-Tech Innovation Board Medical Index has increased by 2.43% in the past month, decreased by 2.53% in the past three months, and has risen by 1.89% year-to-date [1] - The index is based on a reference date of December 30, 2022, with a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: Huatai Medical (10.99%), United Imaging (10.25%), Aibo Medical (6.82%), Yirui Technology (6.61%), Nanwei Medical (5.29%), Shengxiang Biology (5.01%), Xinmai Medical (4.65%), Haier Biomedical (4.17%), Aohua Endoscopy (3.77%), and Yahui Long (3.65%) [1] - The index's holdings are entirely composed of companies listed on the Shanghai Stock Exchange, with a 100% allocation [1] - In terms of industry composition, medical consumables account for 44.80%, medical devices for 33.62%, and in vitro diagnostics for 21.58% [1] Group 3 - The index samples are adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] - Companies that are delisted or undergo mergers, acquisitions, or splits will be handled according to the calculation and maintenance guidelines [2]